GlaxoSmithKline: European Medicines Agency Accepts Submission of GSK's Marketing Authorisation Application for Zejula in First-Line Maintenance Treatment for Women With Platinum-Responsive Advanced Ovarian Cancer
February 28, 2020
February 28, 2020
LONDON, England, Feb. 28 -- GlaxoSmithKline issued the following news release:
GlaxoSmithKline plc announced that the European Medicines Agency (EMA) has validated the company's Type II Variation (T2V) for Zejula (niraparib) as a maintenance treatment in the first-line setting for women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status. Validation of the T2V confirms that the submission is accepted and begins the formal rev . . .
GlaxoSmithKline plc announced that the European Medicines Agency (EMA) has validated the company's Type II Variation (T2V) for Zejula (niraparib) as a maintenance treatment in the first-line setting for women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status. Validation of the T2V confirms that the submission is accepted and begins the formal rev . . .